Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey

Keywords

• Delphi Technique
• Forecasting
• Humans
• *Idiopathic Pulmonary Fibrosis/diagnosis/therapy
• Surveys and Questionnaires
• personal fees for advisory board work from Boehringer Ingelheim, outside the
• submitted work. Conflict of interest: C. Albera reports personal fees for advisory
• board work, consultancy and steering committee work from Roche, MSD and Bayer,
• personal fees for advisory board work and consultancy from Boheringer Ingelheim,
• Fibrogen and GSK, grants from Roche and Boheringer Ingelheim, during the conduct of
• the study. Conflict of interest: E. Bendstrup reports grants, personal fees and
• non-financial support from Boehringer Ingelheim and Hoffmann la Roche, outside the
• submitted work. Conflict of interest: U. Costabel reports personal fees for
• consultancy and lectures, and non-financial support from Boehringer and Roche,
• personal fees for consultancy from Fibrogen, Pliant Therapeutics and Bristol-Myers
• Squibb, personal fees for lectures from AstraZeneca and Novartis, outside the
• submitted work. Conflict of interest: J.C. Grutters has nothing to disclose.
• Conflict of interest: S. Harari reports personal fees for lectures and advisory
• board work from Roche, grants and personal fees for lectures and advisory board work
• from Actelion and Boehringer Ingelheim, outside the submitted work. Conflict of
• interest: K.A. Johannson reports personal fees, non-financial support and other
• (advisory board work) from Boehringer Ingelheim, personal fees from Hoffman-La Roche
• Ltd, Blade Therapeutics and Theravance, grants from The Chest Foundation, University
• of Calgary Cumming School of Medicine, UCB Biopharma SPRL and Pulmonary Fibrosis
• Society of Calgary, personal fees and non-financial support from Three Lakes
• Foundation, outside the submitted work. Conflict of interest: M. Kreuter reports
• grants and personal fees from Boehringer Ingelheim and Roche, personal fees from
• Galapagos, outside the submitted work. Conflict of interest: I. Strambu reports
• personal fees for advisory board work and lectures from Boehringer Ingelheim,
• personal fees for lectures from Roche Pharma, AstraZeneca and Novartis, personal
• fees for investigation work from Galapagos, outside the submitted work. Conflict of
• interest: C. Vancheri reports grants and personal fees from Roche and Boehringer
• Ingelheim, outside the submitted work. Conflict of interest: F. Varone reports
• personal fees from Boehringer Ingelheim and Roche, outside the submitted work.
• Conflict of interest: P. Vitulo has nothing to disclose. Conflict of interest: W.A.
• Wuyts reports grants from Roche and Boehringer Ingelheim, outside the submitted work
• (paid to institution). Conflict of interest: F. Martinez reports personal fees for
• advisory board work, non-financial support for travel and other from AstraZeneca,
• other (steering committee work and publication) from Afferent/Merck, personal fees
• for advisory board work, data monitoring committee work, steering committee work and
• lectures, non-financial support for travel and other (publication) from Boehringer
• Ingelheim, other (teleconference without compensation) from Bristol Myers Squibb and
• twoXR, other (travel support) from Chiesi, personal fees for lectures and
• non-financial support for travel from Canadian Respiratory Society, CME Outfitters,
• Inova Fairfax, MDMagazine, NYP Methodist Hospital Brooklyn, Miller Communications,
• National Association for Continuing Education, Novartis, Peer View, Rare Diseases
• Healthcare Communications and WebMD/MedScape, personal fees for advisory board work
• and non-financial support for travel from CSL Behring, Sanofi/Regeneron, University
• of Birmingham Alabama, Sunovion and Teva, personal fees for lectures from Dartmouth
• University, France Foundation, New York University, Rockpointe Communications and
• Vindico, personal fees for advisory board work from Gala, Pearl and Verona, personal
• fees for data monitoring committee and advisory board work, and non-financial
• support for travel from Genentech, grants, personal fees for advisory board, data
• monitoring committee and steering committee work, and non-financial support for
• travel from GlaxoSmithKline, other (steering committee without compensation) from
• Nitto, personal fees for steering committee work and non-financial support for
• travel from Patara/Respivant, personal fees for educational activities from
• Physicians Education Resource and UpToDate, personal fees for steering committee
• work from ProMedior, other (data monitoring and steering committee without
• compensation) from Biogen, non-financial support (steering committee) from Veracyte,
• non-financial support for travel and in-kind study support from Zambon,
• non-financial support (consultancy and in-kind study support) from ProTerrix Bio,
• personal fees for consultancy from IQVIA, Raziel and Abvie, outside the submitted
• work. Conflict of interest: G. Raghu reports personal fees and other (consultancy)
• from Boerhinger Ingelheim, Roche, Respivant and Veracyte, other (consultancy and
• data monitoring committee work) from Avalyn, other (consultancy) from BMS, Biogen,
• Blade Therapeutics, Bellerophan, Fibrogen, Gilead, Genentech, Nitto and Promedior,
• and grants from NIH, outside the submitted work.